Stockreport

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB Biotherapeutics, Inc.  (SABS) 
PDF MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platfor [Read more]